209 related articles for article (PubMed ID: 22469394)
1. Leishmania resistance to miltefosine associated with genetic marker.
Cojean S; Houzé S; Haouchine D; Huteau F; Lariven S; Hubert V; Michard F; Bories C; Pratlong F; Le Bras J; Loiseau PM; Matheron S
Emerg Infect Dis; 2012 Apr; 18(4):704-6. PubMed ID: 22469394
[No Abstract] [Full Text] [Related]
2. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
Kumar D; Kulshrestha A; Singh R; Salotra P
Antimicrob Agents Chemother; 2009 Feb; 53(2):835-8. PubMed ID: 19015344
[TBL] [Abstract][Full Text] [Related]
3. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
4. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Escobar P; Yardley V; Croft SL
Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.
Ponte-Sucre A; Gamarro F; Dujardin JC; Barrett MP; López-Vélez R; García-Hernández R; Pountain AW; Mwenechanya R; Papadopoulou B
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006052. PubMed ID: 29240765
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
7. [A case of antimony resistant kala-azar cured with amphotericin B].
Chen SB; Yang CM; Zhang CJ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
[No Abstract] [Full Text] [Related]
8. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
Murray HW
Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
[No Abstract] [Full Text] [Related]
9. Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
Gonçalves G; Campos MP; Gonçalves AS; Medeiros LCS; Figueiredo FB
Parasit Vectors; 2021 Dec; 14(1):599. PubMed ID: 34886876
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
Gangneux JP; Marty P
Sante; 2001; 11(4):257-8. PubMed ID: 11861203
[No Abstract] [Full Text] [Related]
11. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
12. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutics of visceral leishmaniasis: present and future developments.
Sundar S; Singh A
Parasitology; 2018 Apr; 145(4):481-489. PubMed ID: 29215329
[TBL] [Abstract][Full Text] [Related]
14. New insights with miltefosine unresponsiveness in Brazilian Leishmania infantum isolates.
Bhattacharya A; Ouellette M
EBioMedicine; 2018 Nov; 37():13-14. PubMed ID: 30314891
[No Abstract] [Full Text] [Related]
15. Persistent dermal lesions in a patient with previous history of visceral leishmaniasis.
Jaiteh MB; İnkaya AÇ; Üner A; Elçin G; Ergüven S; Kurtulan O; Harxhi A; Akova M
Parasitol Int; 2021 Feb; 80():102197. PubMed ID: 32920054
[TBL] [Abstract][Full Text] [Related]
16. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
Mishra J; Singh S
Exp Parasitol; 2013 Oct; 135(2):397-406. PubMed ID: 23968687
[TBL] [Abstract][Full Text] [Related]
17. Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic.
Srivastava P; Prajapati VK; Rai M; Sundar S
J Clin Microbiol; 2011 Aug; 49(8):3088-91. PubMed ID: 21613432
[TBL] [Abstract][Full Text] [Related]
18. Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.
Murray HW
Antimicrob Agents Chemother; 2000 Nov; 44(11):3235-6. PubMed ID: 11036063
[TBL] [Abstract][Full Text] [Related]
19. Evaluating drug resistance in visceral leishmaniasis: the challenges.
Hendrickx S; Guerin PJ; Caljon G; Croft SL; Maes L
Parasitology; 2018 Apr; 145(4):453-463. PubMed ID: 27866478
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]